These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1296 related items for PubMed ID: 18471512

  • 1. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
    Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P, TAHRS Investigators.
    Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
    [Abstract] [Full Text] [Related]

  • 2. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.
    Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J.
    Hepatology; 2002 Oct; 36(4 Pt 1):941-8. PubMed ID: 12297842
    [Abstract] [Full Text] [Related]

  • 3. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, Ganger D, Jamil K, Pappas SC, REVERSE Study Investigators.
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [Abstract] [Full Text] [Related]

  • 4. Terlipressin and albumin combination treatment in hepatorenal syndrome.
    Danalioglu A, Cakaloglu Y, Karaca C, Aksoy N, Akyuz F, Ozdil S, Demir K, Besisik F, Boztas G, Mungan Z, Kaymakoglu S, Okten A.
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccciii-cccv. PubMed ID: 15244209
    [Abstract] [Full Text] [Related]

  • 5. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.
    von Kalckreuth V, Glowa F, Geibler M, Lohse AW, Denzer UW.
    Z Gastroenterol; 2009 Jan; 47(1):21-6. PubMed ID: 19156588
    [Abstract] [Full Text] [Related]

  • 6. Terlipressin therapy for renal failure in cirrhosis.
    Triantos CK, Samonakis D, Thalheimer U, Cholongitas E, Senzolo M, Marelli L, Leandro G, Patch D, Burroughs AK.
    Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):481-6. PubMed ID: 19952764
    [Abstract] [Full Text] [Related]

  • 7. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
    Sharma P, Kumar A, Shrama BC, Sarin SK.
    Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
    [Abstract] [Full Text] [Related]

  • 8. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?
    Piano S, Morando F, Fasolato S, Cavallin M, Boscato N, Boccagni P, Zanus G, Cillo U, Gatta A, Angeli P.
    J Hepatol; 2011 Aug; 55(2):491-6. PubMed ID: 21334405
    [Abstract] [Full Text] [Related]

  • 9. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.
    Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A.
    J Hepatol; 2007 Oct; 47(4):499-505. PubMed ID: 17560680
    [Abstract] [Full Text] [Related]

  • 10. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.
    Alessandria C, Debernardi-Venon W, Carello M, Ceretto S, Rizzetto M, Marzano A.
    Dig Liver Dis; 2009 Apr; 41(4):298-302. PubMed ID: 19158001
    [Abstract] [Full Text] [Related]

  • 11. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
    Sagi SV, Mittal S, Kasturi KS, Sood GK.
    J Gastroenterol Hepatol; 2010 May; 25(5):880-5. PubMed ID: 20074149
    [Abstract] [Full Text] [Related]

  • 12. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.
    Testro AG, Wongseelashote S, Angus PW, Gow PJ.
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1535-40. PubMed ID: 17784863
    [Abstract] [Full Text] [Related]

  • 13. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
    Moreau R, Lebrec D.
    Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
    [Abstract] [Full Text] [Related]

  • 14. Terlipressin in hepatorenal syndrome: Evidence for present indications.
    Rajekar H, Chawla Y.
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
    [Abstract] [Full Text] [Related]

  • 15. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.
    Saner F, Kavuk I, Lang H, Biglarnia R, Frühauf NR, Schäfers RF, Malagó M, Broelsch CE.
    Eur J Med Res; 2004 Feb 27; 9(2):78-82. PubMed ID: 15090293
    [Abstract] [Full Text] [Related]

  • 16. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P, Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome.
    Hepatology; 2015 Aug 27; 62(2):567-74. PubMed ID: 25644760
    [Abstract] [Full Text] [Related]

  • 17. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study.
    Péron JM, Bureau C, Gonzalez L, Garcia-Ricard F, de Soyres O, Dupuis E, Alric L, Pourrat J, Vinel JP.
    Am J Gastroenterol; 2005 Dec 27; 100(12):2702-7. PubMed ID: 16393223
    [Abstract] [Full Text] [Related]

  • 18. The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study.
    Fimiani B, Guardia DD, Puoti C, D'Adamo G, Cioffi O, Pagano A, Tagliamonte MR, Izzi A.
    Eur J Intern Med; 2011 Dec 27; 22(6):587-90. PubMed ID: 22075285
    [Abstract] [Full Text] [Related]

  • 19. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome.
    Nazar A, Pereira GH, Guevara M, Martín-Llahi M, Pepin MN, Marinelli M, Solá E, Baccaro ME, Terra C, Arroyo V, Ginès P.
    Hepatology; 2010 Jan 27; 51(1):219-26. PubMed ID: 19877168
    [Abstract] [Full Text] [Related]

  • 20. Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome.
    Saner FH, Canbay A, Gerken G, Broelsch CE.
    Expert Rev Gastroenterol Hepatol; 2007 Dec 27; 1(2):207-17. PubMed ID: 19072411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.